Esperion Therapeutics | ESPR - Выручка от реализации





Продажи Изменить Дата
AbbVie USD 16.62B 840M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
Amarin USD 49.22M 451K 2025-12
Amgen USD 9.9B 340M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Cipla INR 75.18B 710M 2025-12
CSL USD 8.33B 4.79B 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Daiichi Sankyo JPY 558.11B 57.35B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Geron USD 48.02M 820K 2025-12
Grifols EUR 2.34B 33.3M 2026-03
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 678M 342M 2025-12
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Sanofi EUR 11.3B 1.13B 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12